# Eloralintide

Source: https://aminodesk.com/library/eloralintide
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

Eloralintide is an experimental once-weekly injection from Eli Lilly that acts on the amylin receptor, a different target from the GLP-1 drugs. A mid-stage trial showed weight loss of up to about 20%. It is in Phase 3 trials and cannot be prescribed.

- **Legal lane:** investigational. Not FDA-approved and not available by prescription.
- **Evidence grade:** B. One strong mid-stage trial; Phase 3 results not yet in.
- **Form:** weekly injection under the skin
- **Developer:** Eli Lilly

## What it is

Amylin is a hormone released with insulin that helps produce the feeling of fullness. Eloralintide is a selective amylin receptor agonist, formerly known as LY3841136. It belongs to the same new class as [cagrilintide](https://aminodesk.com/library/cagrilintide).

## What the evidence shows

The Phase 2 trial enrolled 263 adults with obesity, or overweight with a related condition, and without type 2 diabetes. At 48 weeks, average weight loss ranged from 9.5% on the lowest dose to 20.1% on the highest, against 0.4% on placebo. Lilly presented the results in November 2025.

In September 2026 Lilly reported that eloralintide combined with tirzepatide produced more weight loss than tirzepatide alone in a 48-week trial in adults with obesity and type 2 diabetes.

These are company-reported mid-stage results. Phase 3 trials, which are larger and longer, decide whether the effect and the safety hold up.

## Legal status

- Not FDA-approved. Phase 3 trials of eloralintide alone are under way.
- Lilly said it would start Phase 3 trials of the combination with tirzepatide in the last quarter of 2026.
- The only lawful way to receive it is as a participant in a trial. Anything sold online under this name has no regulated source.

## Reported dosing

**No approved dose exists.**

The Phase 2 trial tested 1 mg, 3 mg, 6 mg and 9 mg once a week, and two schedules that stepped up to 9 mg. Those are trial doses in a monitored study, not a recommendation.

## Safety

- Lilly described the tolerability as favorable in Phase 2. Full safety data will come from Phase 3.
- Long-term safety is unknown.
- Products sold as eloralintide outside a trial have no verified contents.

## Common questions

### Is eloralintide FDA-approved?

No. It is in Phase 3 trials.

### How much weight did people lose on eloralintide?

Between 9.5% and 20.1% at 48 weeks in the Phase 2 trial, depending on dose, against 0.4% on placebo.

### How is eloralintide different from a GLP-1?

It acts on the amylin receptor, a separate fullness signal.

### Can I get eloralintide now?

Only by taking part in a clinical trial.

## Sources

- [Lilly: Phase 2 results for eloralintide (November 6, 2025)](https://investor.lilly.com/node/53246)
- [Lilly: eloralintide with tirzepatide Phase 2b results and Phase 3 plans (September 30, 2026)](https://investor.lilly.com/node/54991/pdf)
- [BioSpace: trial population and analyst reaction](https://www.biospace.com/drug-development/lillys-amylin-agonist-headed-to-phase-iii-after-eliciting-up-to-20-weight-loss)
- [Drug Topics: dose groups in the Phase 2 trial](https://www.drugtopics.com/view/eloralintide-reduces-weight-by-9-5-to-20-1-for-patients-with-obesity)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
